Table of Contents

1.0 Description of the Procedure, Product, or Service ........................................................................... 1
1.1 Definitions ......................................................................................................................................... 3
  1.1.1 Donor Lymphocyte Infusion (DLI) ......................................................................................... 3

2.0 Eligibility Requirements .................................................................................................................... 3
  2.1 Provisions ....................................................................................................................................... 3
    2.1.1 General ................................................................................................................................ 3
    2.1.2 Specific .................................................................................................................................. 3
  2.2 Special Provisions ............................................................................................................................ 4
    2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age ................................................................. 4
    2.2.2 EPSDT does not apply to NCHC beneficiaries ................................................................. 5
    2.2.3 Health Choice Special Provision for a Health Choice Beneficiary age 6 through 18 years of age ......................................................... 5

3.0 When the Procedure, Product, or Service Is Covered ...................................................................... 5
  3.1 General Criteria Covered ................................................................................................................ 5
  3.2 Specific Criteria Covered ................................................................................................................ 5
    3.2.1 Specific criteria covered by both Medicaid and NCHC ..................................................... 5
    3.2.2 Policy Guidelines ................................................................................................................... 6
    3.2.3 Medicaid Additional Criteria Covered ............................................................................... 6
    3.2.4 NCHC Additional Criteria Covered ..................................................................................... 6

4.0 When the Procedure, Product, or Service Is Not Covered ............................................................... 6
  4.1 General Criteria Not Covered ....................................................................................................... 6
  4.2 Specific Criteria Not Covered ...................................................................................................... 7
    4.2.1 Specific Criteria Not Covered by both Medicaid and NCHC .............................................. 7
    4.2.2 Medicaid Additional Criteria Not Covered ................................................................. 7
    4.2.3 NCHC Additional Criteria Not Covered ............................................................................. 7

5.0 Requirements for and Limitations on Coverage ............................................................................. 7
  5.1 Prior Approval .............................................................................................................................. 7
  5.2 Prior Approval Requirements .................................................................................................... 7
    5.2.1 General ................................................................................................................................ 7
    5.2.2 Specific .................................................................................................................................. 8
  5.3 Specific Transplant Prior Approval Requirements ........................................................................ 8

6.0 Providers Eligible to Bill for the Procedure, Product, or Service ..................................................... 8
  6.1 Provider Qualifications and Occupational Licensing Entity Regulations ..................................... 9
  6.2 Provider Certifications .................................................................................................................. 9

7.0 Additional Requirements .................................................................................................................. 9
Hematopoietic Stem-Cell Transplantation for Chronic Myeloid Leukemia (CML)

7.1 Compliance ......................................................................................................................... 9

8.0 Policy Implementation/Revision Information........................................................................ 10

Attachment A: Claims-Related Information................................................................................ 12
A. Claim Type ....................................................................................................................... 12
B. International Classification of Diseases and Related Health Problems, Tenth Revisions,
   Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) ................... 12
C. Code(s) .............................................................................................................................. 12
D. Modifiers ........................................................................................................................... 12
E. Billing Units ...................................................................................................................... 12
F. Place of Service ................................................................................................................ 13
G. Co-payments ..................................................................................................................... 13
H. Reimbursement ............................................................................................................... 13
I. Billing for Donor Expenses .............................................................................................. 13
1.0 Description of the Procedure, Product, or Service

Hematopoietic Stem-Cell Transplantation

Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiation therapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HSCT) or from a donor (allogeneic HSCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD).

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HSCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allogeneic HSCT. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA A, B, and DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci.

Conventional Preparative Conditioning for HSCT

The conventional (“classical”) practice of allogeneic HSCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that develops after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects that include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allogeneic HSCT, immune suppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility of the patient to opportunistic infections.
The success of autologous HSCT is predicated on the ability of cytotoxic chemotherapy with or without radiation to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient prior to undergoing bone marrow ablation. As a consequence, autologous HSCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HSCT are susceptible to chemotherapy-related toxicities and opportunistic infections prior to engraftment, but not GVHD.

Reduced-Intensity Conditioning for Allogeneic HSCT
Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is not only to reduce disease burden, but also to minimize as much as possible associated treatment-related morbidity and nonrelapse mortality (NRM) in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative, to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allogeneic HSCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For the purposes of this Policy, the term reduced-intensity conditioning will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that is characterized by the presence of a chromosomal abnormality called the Philadelphia chromosome, which results from reciprocal translocation between the long arms of chromosomes 9 and 22. This cytogenetic change results in constitutive activation of BCR-ABL, a tyrosine kinase (TK) that stimulates unregulated cell proliferation, inhibition of apoptosis, genetic instability, and perturbation of the interactions between CML cells and the bone marrow stroma only in malignant cells. CML accounts for about 15% of newly diagnosed cases of leukemia in adults and occurs in about 1 to 2 cases per 100,000 adults.

The natural history of the disease consists of an initial (indolent) chronic phase, lasting a median of three years that typically transforms into an accelerated phase, followed by a "blast crisis," which is usually the terminal event. Most patients present in chronic phase, often with nonspecific symptoms that are secondary to anemia and splenomegaly. CML is diagnosed based on the presence of the Philadelphia chromosome abnormality by routine cytogenetics, or by detection of abnormal BCR-ABL products by fluorescence in situ hybridization or molecular studies, in the setting of persistent unexplained leukocytosis. Conventional-dose chemotheraphy regimens used for chronic-phase disease can induce multiple remissions and delay the onset of blast crisis to a median of 4–6 years. However, successive remissions are invariably shorter and more difficult to achieve than their predecessors. Historically the only curative therapy for CML in blast phase was HSCT, and HSCT was used more widely earlier in the disease process given the lack of other therapies for chronic phase CML. Drug therapies for chronic phase CML were limited to
nonspecific agents including busulfan, hydroxyurea, and interferon-alpha.

Imatinib mesylate (Gleevec®), a selective inhibitor of the abnormal BCR-ABL TK protein, is considered the treatment of choice for newly diagnosed CML. While imatinib can be highly effective in suppressing CML in most patients, it is not curative and is ineffective in 20% to 30%, initially or due to development of BCR-ABL mutations that cause resistance to the drug. Even so, the overall survival (OS) of patients who present in chronic phase is greater than 95% at 2 years and 80% to 90% at 5 years.

Two other TK inhibitors (TKIs, dasatinib, nilotinib) have received marketing approval from the U.S. Food and Drug Administration (FDA) to treat CML as front-line therapy or following failure or patient intolerance of imatinib. Two additional TKIs, bosutinib and ponatinib, have been approved for use in patients resistant or intolerant to prior therapy.

For patients who progress on imatinib, the therapeutic options include increasing the imatinib dose, changing to another TKI, or allo-HSCT. Detection of BCR-ABL mutations may be important in determining an alternative TKI; the presence of T315/mutation is associated with resistance to all TKIs and should indicate need for allo-HSCT or an experimental therapy. TKIs have been associated with long-term remissions; however, if progression occurs on TKI therapy, allo-HSCT is generally indicated and offers the potential for cure.

1.1 Definitions

1.1.1 Donor Lymphocyte Infusion (DLI)

A type of therapy in which lymphocytes from the blood of a donor are given to a beneficiary who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells.

2.0 Eligibility Requirements

2.1 Provisions

2.1.1 General

(The term “General” found throughout this policy applies to all Medicaid and NCHC policies)

a. An eligible beneficiary shall be enrolled in either:
   1. the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise); or
   2. the NC Health Choice (NCHC is NC Health Choice program, unless context clearly indicates otherwise) Program on the date of service and shall meet the criteria in Section 3.0 of this policy.

b. Provider(s) shall verify each Medicaid or NCHC beneficiary’s eligibility each time a service is rendered.

c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.

d. Following is only one of the eligibility and other requirements for participation in the NCHC Program under GS 108A-70.21(a): Children must be between the ages of 6 through 18.

2.1.2 Specific

(The term “Specific” found throughout this policy only applies to this policy)
a. Medicaid
None Apply.

b. NCHC
None Apply.

2.2 Special Provisions

2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age

a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

1. that is unsafe, ineffective, or experimental or investigational.
2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary “to correct or ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary’s health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

b. EPSDT and Prior Approval Requirements

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
2. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below.

*NCTracks Provider Claims and Billing Assistance Guide:*
https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html

EPSDT provider page: https://medicaid.ncdhhs.gov/

2.2.2 **EPSDT does not apply to NCHC beneficiaries**

2.2.3 **Health Choice Special Provision for a Health Choice Beneficiary age 6 through 18 years of age**

NC Medicaid shall deny the claim for coverage for an NCHC beneficiary who does not meet the criteria within *Section 3.0* of this policy. Only services included under the NCHC State Plan and the NC Medicaid clinical coverage policies, service definitions, or billing codes are covered for an NCHC beneficiary.

3.0 **When the Procedure, Product, or Service Is Covered**

*Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for Medicaid Beneficiaries under 21 Years of Age.*

3.1 **General Criteria Covered**

Medicaid and NCHC shall cover the procedure, product, or service related to this policy when medically necessary, and:

a. the procedure, product, or service is individualized, specific, and consistent with symptoms or confirmed diagnosis of the illness or injury under treatment, and not in excess of the beneficiary’s needs;

b. the procedure, product, or service can be safely furnished, and no equally effective and more conservative or less costly treatment is available statewide; and

c. the procedure, product, or service is furnished in a manner not primarily intended for the convenience of the beneficiary, the beneficiary’s caretaker, or the provider.

3.2 **Specific Criteria Covered**

3.2.1 **Specific criteria covered by both Medicaid and NCHC**

Medicaid and NCHC shall cover Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia in the following situations:

a. Allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimen may be considered medically necessary as a treatment of chronic myeloid leukemia (refer to Subsection 3.2.2 Policy Guidelines); or

b. Allogeneic HSCT using a reduced-intensity conditioning (RIC) regimen may be considered medically necessary as a treatment of chronic myeloid leukemia in patients who meet clinical criteria for an allogeneic HSCT but who are not considered candidates for a myeloablative conditioning allogeneic HSCT (refer to Subsection 3.2.2 Policy Guidelines).
c. Donor lymphocyte infusion (DLI) (refer to Subsection 1.1) is considered medically necessary and, therefore, covered following allogeneic hematopoietic stem cell transplantation (HSCT) that is medically necessary for the treatment of CML that has relapsed or is refractory, to prevent relapse in the setting of a high risk of relapse, or to convert an individual from mixed to full donor chimerism.

3.2.2 Policy Guidelines
Some patients for whom a conventional myeloablative allotransplant could be curative may be considered candidates for reduced-intensity conditioning (RIC) allogeneic SCT. These include patients whose age (typically older than 60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) preclude use of a standard myeloablative conditioning regimen.

For patients who qualify for a myeloablative allogeneic SCT on the basis of clinical status, either a myeloablative or RIC regimen may be considered medically necessary.

The National Comprehensive Cancer Network (NCCN) guidelines on Chronic Myelogenous Leukemia recommend allogeneic bone marrow transplant for the treatment of primary CML and CML with disease progression. However, autologous bone marrow transplant for CML is not addressed in these guidelines.

3.2.3 Medicaid Additional Criteria Covered
None Apply.

3.2.4 NCHC Additional Criteria Covered
None Apply.

4.0 When the Procedure, Product, or Service Is Not Covered

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for Medicaid Beneficiaries under 21 Years of Age.

4.1 General Criteria Not Covered
Medicaid and NCHC shall not cover the procedure, product, or service related to this policy when:

a. the beneficiary does not meet the eligibility requirements listed in Section 2.0;

b. the beneficiary does not meet the criteria listed in Section 3.0;

c. the procedure, product, or service duplicates another provider’s procedure, product, or service; or

d. the procedure, product, or service is experimental, investigational, or part of a clinical trial.
4.2 Specific Criteria Not Covered

4.2.1 Specific Criteria Not Covered by both Medicaid and NCHC

Medicaid and NCHC shall not cover Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia in the following situations:

a. Autologous hematopoietic stem cell transplantation as a treatment of CML;

b. When the beneficiary’s psychosocial history limits the beneficiary’s ability to comply with pre- and post-transplant medical care; or

c. When current beneficiary or caretaker non-compliance would make compliance with a disciplined medical regimen improbable.

4.2.2 Medicaid Additional Criteria Not Covered

None Apply.

4.2.3 NCHC Additional Criteria Not Covered

a. NCGS § 108A-70.21(b) “Except as otherwise provided for eligibility, fees, deductibles, copayments, and other cost sharing charges, health benefits coverage provided to children eligible under the Program shall be equivalent to coverage provided for dependents under North Carolina Medicaid Program except for the following:

1. No services for long-term care.

2. No nonemergency medical transportation.

3. No EPSDT.

4. Dental services shall be provided on a restricted basis in accordance with criteria adopted by the Department to implement this subsection.”

5.0 Requirements for and Limitations on Coverage

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for Medicaid Beneficiaries under 21 Years of Age.

5.1 Prior Approval

Medicaid and NCHC shall require prior approval for Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia. The provider shall obtain prior approval before rendering Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.

If prior approval has been given for Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia, actual donor transplant-related medical expenses (procuring, harvesting, short-term storing and all associated laboratory costs) are covered.

If prior approval has been given for allogeneic HSCT for Chronic Myeloid Leukemia (CML) and a donor lymphocyte infusion (DLI) is later indicated (refer to Section 3.2), separate prior approval shall not be required for the DLI procedure.

5.2 Prior Approval Requirements

5.2.1 General

The provider(s) shall submit to the Department of Health and Human Services (DHHS) Utilization Review Contractor the following:
a. the prior approval request; and
b. all health records and any other records that support the beneficiary has met the specific criteria in Subsection 3.2 of this policy.

5.2.2 Specific
None Apply.

5.3 Specific Transplant Prior Approval Requirements
The provider(s) shall submit the following to the NC Medicaid transplant nurse consultant:

a. Letter of medical necessity signed by the attending transplant physician, which documents indications for transplant, regimens and dates, the social history and the transplant evaluation;

b. All health care records and any other records that support the beneficiary has met the specific criteria in Subsection 3.2 of this policy including:
   1. Lab results (less than three months old) to include Complete Blood Count (CBC), complete electrolytes, liver enzymes, Prothrombin Time (PT), International Normalized Ratio (INR), glucose and A1C (Glycated Hemoglobin if Type I or Type II diabetic), and blood type;
   2. Serologies: to include Human Immunodeficiency Virus (HIV), Hepatitis panel, Rapid Plasma Reagin (RPR), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Varicella, Rubella, Herpes Simplex Virus (HSV) I/II, and toxoplasmosis. (Positive serology results may be reported that are greater than three months old);
   3. Diagnostic studies (less than six months old) required in a complete packet include:
      A. Cardiac: Echocardiogram, Electrocardiogram (ECG), and/or cardiac catheterization as appropriate for beneficiary’s clinical status;
      B. Pulmonary: Pulmonary Function Test if beneficiary has cardiac or pulmonary issues, or a history of smoking; and
      C. Chest x-ray for all transplant candidates;
   4. Other diagnostic tests may be requested as appropriate;
   5. Beneficiary’s height and weight
   6. All diagnostic and procedure results, including bone marrow aspiration (not more than six months old)

c. Complete psychological and social evaluation to include:
   1. beneficiary’s medical compliance;
   2. beneficiary’s support network;
   3. post-transplant care plan, with identification of primary and secondary care providers; and
   4. history of mental health issues/substance use/legal issues

d. Beneficiaries with a psychiatric history are required to have an evaluation by a psychiatrist with expertise in evaluating the specific psychiatric issues that relate to transplant candidates.

6.0 Providers Eligible to Bill for the Procedure, Product, or Service
To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

a. meet Medicaid or NCHC qualifications for participation;
b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and
c. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

6.1 Provider Qualifications and Occupational Licensing Entity Regulations

None Apply.

6.2 Provider Certifications

None Apply.

7.0 Additional Requirements

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for Medicaid Beneficiaries under 21 Years of Age.

7.1 Compliance

Provider(s) shall comply with the following in effect at the time the service is rendered:

a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and
b. All NC Medicaid’s clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).
8.0 Policy Implementation/Revision Information

Original Effective Date: July 1, 1987

Revision Information:

<table>
<thead>
<tr>
<th>Date</th>
<th>Section Revised</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/2005</td>
<td>Entire Policy</td>
<td>Policy was updated to include coverage criteria effective with approved date of State Plan amendment 4/1/05.</td>
</tr>
<tr>
<td>09/01/2005</td>
<td>Section 2.2</td>
<td>The special provision related to EPSDT was revised.</td>
</tr>
<tr>
<td>12/01/2005</td>
<td>Section 2.2</td>
<td>The Web address for DMA’s EDPST policy instructions was added to this section.</td>
</tr>
<tr>
<td>12/01/2006</td>
<td>Sections 2.2</td>
<td>The special provision related to EPSDT was revised.</td>
</tr>
<tr>
<td>12/01/2006</td>
<td>Sections 3.0 and 4.0</td>
<td>A note regarding EPSDT was added to these sections.</td>
</tr>
<tr>
<td>05/01/2007</td>
<td>Sections 2 through 4</td>
<td>EPSDT information was revised to clarify exceptions to policy limitations for recipients under 21 years of age.</td>
</tr>
<tr>
<td>05/01/2007</td>
<td>Attachment A</td>
<td>Added the UB-04 as an accepted claims form.</td>
</tr>
<tr>
<td>07/01/2010</td>
<td>Throughout</td>
<td>Session Law 2009-451, Section 10.31(a) Transition of NC Health Choice Program administrative oversight from the State Health Plan to the Division of Medical Assistance (DMA) in the NC Department of Health and Human Services.</td>
</tr>
<tr>
<td>01/01/2012</td>
<td>Throughout</td>
<td>Policy updated to reflect current community standards and changing transplant protocols.</td>
</tr>
<tr>
<td>01/01/2012</td>
<td>Throughout</td>
<td>To be equivalent where applicable to NC DMA’s Clinical Coverage Policy # 11A-3 under Session Law 2011-145, § 10.41.(b)</td>
</tr>
<tr>
<td>03/12/2012</td>
<td>Throughout</td>
<td>Technical changes to merge Medicaid and NCHC current coverage into one policy.</td>
</tr>
<tr>
<td>10/01/2015</td>
<td>All Sections and Attachments</td>
<td>Updated policy template language and added ICD-10 codes to comply with federally mandated 10/1/2015 implementation where applicable.</td>
</tr>
<tr>
<td>03/01/2017</td>
<td>Attachment A, Section B</td>
<td>Replaced and updated ICD-10 codes.</td>
</tr>
<tr>
<td>03/15/2019</td>
<td>Table of Contents</td>
<td>Added, “To all beneficiaries enrolled in a Prepaid Health Plan (PHP): for questions about benefits and services available on or after November 1, 2019, please contact your PHP.”</td>
</tr>
<tr>
<td>03/15/2019</td>
<td>All Sections and Attachments</td>
<td>Updated policy template language.</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Throughout</td>
<td>Removed “&amp; Bone Marrow” from title. Changed “Myelogenous” to “Myeloid.”</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Section 1.0</td>
<td>CML description brought up to date.</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Section 1.1</td>
<td>Definition added for donor lymphocyte infusion (DLI).</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Section 3.2.1</td>
<td>Criteria added for DLI coverage.</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Section 5.1</td>
<td>Added text that if PA has been given for allogeneic HSCT and DLI is later indicated, separate PA is not required for the DLI procedure.</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Section 5.3</td>
<td>“Indications for transplant” added to letter of medical</td>
</tr>
<tr>
<td>Date</td>
<td>Section/Attachment</td>
<td>Change</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Section 7.0</td>
<td>Removed the following statements: FDA approved procedures, products, and devices for implantation must be utilized. A statement signed by the surgeon certifying all FDA requirements for the implants, products, and devices must be retained in the beneficiary’s medical record and made available for review upon request. This text is not applicable to this policy.</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>Attachment A</td>
<td>Added the UB-04 as an accepted claims form. Removed all CPT, HCPCS, and ICD-10 codes.</td>
</tr>
<tr>
<td>01/15/2020</td>
<td>Table of Contents</td>
<td>Updated policy template language, “To all beneficiaries enrolled in a Prepaid Health Plan (PHP): for questions about benefits and services available on or after implementation, please contact your PHP.”</td>
</tr>
<tr>
<td>01/15/2020</td>
<td>Attachment A</td>
<td>Added, “Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines”</td>
</tr>
</tbody>
</table>
Attachment A: Claims-Related Information

Provider(s) shall comply with the, NCTracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid’s clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid and NCHC:

A. Claim Type

Professional (CMS-1500/837P transaction)

Institutional (UB-04/83711)

Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.

B. International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS)

Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.

C. Code(s)

Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy.

If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

Unlisted Procedure or Service

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions for Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service.

D. Modifiers

Provider(s) shall follow applicable modifier guidelines.

E. Billing Units

Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).
F. **Place of Service**
   Inpatient hospital, Outpatient hospital.

G. **Co-payments**
   For Medicaid refer to Medicaid State Plan:

   For NCHC refer to NCHC State Plan:

H. **Reimbursement**
   Provider(s) shall bill their usual and customary charges.
   For a schedule of rates, refer to: [https://medicaid.ncdhhs.gov/](https://medicaid.ncdhhs.gov/)

I. **Billing for Donor Expenses**
   1. **Billing for Donor Expenses for Medicaid Beneficiaries**
      Donor transplant-related medical expenses are billed on the Medicaid beneficiary’s transplant claim using the beneficiary’s Medicaid identification number.
      Medicaid reimburses only for the actual donor’s transplant-related medical expenses. Medicaid does not reimburse for unsuccessful donor searches.

   2. ** Billing for Donor Expenses for NCHC Beneficiaries**
      Donor transplant-related medical expenses donors are billed on the NCHC beneficiary’s transplant claim.
      NCHC reimburses only for the actual donor’s transplant-related medical expenses. NCHC does not reimburse for unsuccessful donor searches.